Scientific Research and Essays

  • Abbreviation: Sci. Res. Essays
  • Language: English
  • ISSN: 1992-2248
  • DOI: 10.5897/SRE
  • Start Year: 2006
  • Published Articles: 2768

Full Length Research Paper

Inhibition of DPP IV is a suggested mechanism of the immunomodulatory effects of sparfloxacin

Suhair Saleh1*, Mohammad Mohammad2, Sundus H. Mashallah1, Eman Elayeh2, Ihab AlMasri3, Hatim S. AlKhatib2, Mohammad Fararjeh4 and Yasser Bustanji2
1Faculty of Pharmacy, Applied Science University, Amman, Jordan. 2Faculty of Pharmacy, University of Jordan, Amman, Jordan. 3Faculty of Pharmacy, Al-Azhar University, Gaza, Gaza Strip, Palestine. 4Faculty of Allied Health Sciences, The Hashemite University, Zarqa, Jordan.
Email: [email protected]

  •  Accepted: 23 March 2011
  •  Published: 23 January 2012


Sparfloxacin is the first marketed amino difluoroquinolone. It is currently marketed in many countries in the world and used widely for the management of urinary tract or respiratory tract infections. Fluoroquinolones could modulate both cellular and humoral immunity. The results of this study showed that Sparfloxacin could significantly suppress the proliferation of both stimulated Balb/c splenocytes and stimulated murine macrophages. Moreover, the release of the IL-6 from these cells was also suppressed. Interestingly, Sparfloxacin inhibits dipeptidyl peptidase IV enzyme (DPP IV) in a dose dependent manner with an IC50 of 29.6 μM. These findings suggest that DPP IV inhibition by Sparfloxacin could be one of the mechanisms by which Sparfloxacin exerts its immune-modulatory activities.


Key words: Sparfloxacin, fluoroquinolones, dipeptidyl peptidase, DPP IV, immunomodulatory, IL-6, mitogen, raw cells.